文献速递神经肿瘤

鞣花酸增强贝伐珠单抗对胶质母细胞瘤的体外抗肿瘤效果

Ellagic Acid Enhances the Antitumor Efficacy of Bevacizumab in an In Vitro Glioblastoma Model.
PubMed 文献 · World Neurosurg · 2019-09-10

本研究在大鼠C6胶质瘤细胞系中观察鞣花酸(EA)联合贝伐珠单抗(BEV)的体外抗肿瘤效果。EA(100 μmol/L)联合BEV(100 ng/mL)处理24、48、72小时,可显著降低细胞活力;EA无论是否联合BEV均下调MGMT表达,联合处理仅在72小时降低MDR1表达,且EA在蛋白水平时间依赖性影响p53和caspase-3。提示EA联合BEV可能通过抑制MGMT和时间依赖性抑制MDR1发挥抗增殖作用。

要点

  • EA联合BEV显著降低C6胶质瘤细胞活力,作用覆盖24、48、72小时。
  • EA无论是否联合BEV均显著下调MGMT表达,早期即可出现。
  • EA联合BEV仅在72小时降低MDR1表达,蛋白水平影响p53和caspase-3。

核心结论

  • EA联合BEV在体外对C6胶质瘤细胞具有抗增殖效果,可能通过抑制MGMT表达和时间依赖性抑制MDR1实现。
  • EA联合BEV可能成为耐药胶质瘤的替代治疗选择。

研究设计与样本

  • 体外研究,使用大鼠C6胶质瘤细胞系。
  • EA以100 μmol/L浓度联合BEV以100 ng/mL浓度处理24、48、72小时。
  • 采用BrdU免疫组化检测细胞增殖,免疫组化及H-Score评估p53和caspase-3蛋白水平,RT-PCR检测MDR1、MGMT、caspase-3和p53相关蛋白的表达谱。

主要发现

  • EA联合BEV在所有孵育时间点均显著降低C6胶质瘤细胞活力。
  • EA无论是否联合BEV均显著下调MGMT表达,甚至在处理后早期即可出现。
  • EA联合BEV仅在72小时降低MDR1表达。
  • EA在蛋白水平时间依赖性影响p53和caspase-3,但在基因水平无影响。

临床怎么用

  • EA联合BEV可能为耐药胶质瘤提供替代治疗思路,但需进一步体内和临床研究验证。

局限性

  • 研究仅为体外C6胶质瘤细胞系实验,结论尚未在体内或临床中得到验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The anticarcinogenic effect of ellagic acid (EA), a natural phenol of fruits and vegetables, has been investigated in several types of tumors. The combined effect of EA with bevacizumab (BEV), a common drug used in treatment of recurrent glioma, on glioblastoma has not been reported. This study observed the combined effect of EA with BEV on the expression profile of the C6 glioma cell line. METHODS: Rat C6 glioma cells were treated with EA at 100 μmol/L concentration in combination with BEV at 100 ng/mL concentration for 24, 48, and 72 hours. Cell proliferation was detected by 5-bromo-2'-deoxyuridine immunohistochemistry, and p53 and caspase-3 protein levels were determined by immunohistochemistry and assessed by the H-Score. Expression profiles for P-glycoprotein (MDR1), O6-methylguanine DNA methyltransferase (MGMT), caspase-3, and p53 related proteins were detected by reverse transcriptase polymerase chain reaction after EA treatment with or without BEV. RESULTS: EA combined with BEV conspicuously reduced the cell viability of C6 glioma cells for all incubation times. EA significantly downregulated expression of MGMT regardless of combination with BEV even in the early hours after treatment. Combined EA and BEV reduced MDR1 expression only at 72 hours. EA affected the apoptotic proteins of p53 and caspase-3 at protein level in a time-dependent manner, but not at gene level. CONCLUSIONS: This study suggests successful antiproliferative efficacy of EA combined with BEV, probably through inhibition of MGMT expression and time-dependent inhibition of MDR1. EA combined with BEV may be an alternative treatment for drug-resistant gliomas.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Çetin A, Biltekin B, Degirmencioglu S, et al. Ellagic Acid Enhances the Antitumor Efficacy of Bevacizumab in an In Vitro Glioblastoma Model. World Neurosurg. 2019. PMID: 31518741. doi:10.1016/j.wneu.2019.08.257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。